Prognostic significance of extracellular matrix degrading enzymes-cathepsin l and matrix metalloproteases-2 [MMP-2] in human pancreatic cancer

Cancer Investigation

Volumn 31, Issue 7, 2013, Pages 461-471

  Singh, Nidhi ^a   Das, Prasenjit ^a   Datta Gupta, Siddhartha ^a   Sahni, Peush ^a   Pandey, R M ^a   Gupta, Surabhi ^a   Chauhan, Shyam S ^a   Saraya, Anoop ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Invasion and metastasis; Pancreatic cancer; Prognostic studies

Indexed keywords

CATHEPSIN L; GELATINASE A;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA;

ADENOCARCINOMA; ADULT; AGED; CATHEPSIN L; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 84881308522     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357907.2013.820318     Document Type: Article

References (49)

1. DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology 1999;117:1464-1484
2. Wray CJ, Ahmad SA,Matthews JB, Lowy AM. Surgery for pancreatic cancer: Recent controversies and current practice. Gastroenterology 2005;128:1626-1641
3. Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, DooleyWC, Coleman J, Pitt HA. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995;221:721-731; discussion 731-723
4. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-379
5. DeWever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003;200:429-447
6. Hwang RF,Moore T, ArumugamT, RamachandranV, Amos KD, Rivera A, Ji B, Evans DB, Logsdon CD. Cancer-Associated stromal fibroblasts promote pancreatic tumor progression.Cancer Res 2008;68:918-926
7. Reiser-Erkan C, Erkan M, Pan Z, Bekasi S, Giese NA, Streit S, Michalski CW, Friess H, Kleeff J. Hypoxia-inducible protooncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer Biol Ther 2008;7:1352-1359
8. Sato N, Maehara N, Goggins M. Gene expression profiling of tumor-stromal interactions between pancreatic cancer cells and stromal fibroblasts. Cancer Res 2004;64:6950-6956
9. DenhardtDT, GreenbergAH, Egan SE,Hamilton RT, Wright JA. Cysteine proteinase cathepsin L expression correlates closely with the metastatic potential of H-ras-Transformed murine fibroblasts. Oncogene 1987;2:55-59
10. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999;43 (Suppl):S42-S51
11. Kobayashi H, Schmitt M, Goretzki L, Chucholowski N, Calvete J, Kramer M, Gunzler WA, Janicke F, Graeff H. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-Type plasminogen activator (Pro-uPA). J Biol Chem 1991;266:5147-5152
12. Lah TT, Kokalj-Kunovar M, Strukelj B, Pungercar J, Barlic-Maganja D, Drobnic-Kosorok M, Kastelic L, Babnik J, Golouh R, Turk V. Stefins and lysosomal cathepsins B, L and D in human breast carcinoma. Int J Cancer 1992;50:36-44
13. Sloane BF. Cathepsin B and cystatins: Evidence for a role in cancer progression. Semin Cancer Biol 1990;1:137-152
14. Collette J, Bocock JP, Ahn K, Chapman RL, Godbold G, Yeyeodu S, Erickson AH. Biosynthesis and alternate targeting of the lysosomal cysteine protease cathepsin L. Int Rev Cytol 2004;241:1-51
15. Nomura T, Katunuma N. Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J Med Invest 2005;52:1-9
16. Lankelma JM, Voorend DM, Barwari T, Koetsveld J, Van der Spek AH, De Porto AP, Van Rooijen G, Van Noorden CJ. Cathepsin L, target in cancer treatment? Life Sci 2010;86:225-233
17. Miyamoto K, Iwadate M, Yanagisawa Y, Ito E, Imai J, Yamamoto M, Sawada N, Saito M, Suzuki S, Nakamura I, Ohki S, Saze Z, KogureM,GotohM, OmicronbaraK,Ohira H, Tasaki K, AbeM, Goshima N, Watanabe S, Waguri S, Takenoshita S. Cathepsin L is highly expressed in gastrointestinal stromal tumors. Int J Oncol 2011;39:1109-1115
18. Thomssen C, Schmitt M, Goretzki L, Oppelt P, Pache L, Dettmar P, Janicke F, Graeff H. Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer. Clin Cancer Res 1995;1:741-746
19. Yan JA, Xiao H, Ji HX, Shen WH, Zhou ZS, Song B, Chen ZW, Li WB. Cathepsin L is associated with proliferation and clinical outcome of urothelial carcinoma of the bladder. J Int Med Res 2010;38:1913-1922
20. Niedergethmann M,Wostbrock B, Sturm JW, Willeke F, Post S, Hildenbrand R. Prognostic impact of cysteine proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma. Pancreas 2004;29:204-211
21. Birkedal-Hansen H. Proteolytic remodelling of extracellular matrix. Curr Opin Cell Biol 1995;7:728-735
22. Ishikawa S, Takenaka K, Yanagihara K, Miyahara R, Kawano Y, Otake Y, Hasegawa S, Wada H, Tanaka F. Matrix metalloproteinase-2 status in stromal fibroblasts, not in tumor cells, is a significant prognostic factor in non-small-cell lung cancer. Clin Cancer Res 2004;10:6579-6585
23. Ross JS, Kaur P, Sheehan CE, Fisher HA, Kaufman RA, Jr., Kallakury BV. Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod Pathol 2003;16:198-205
24. Sivula A, Talvensaari-Mattila, A., Lundin, J., Joensuu, H., Haglund, C., Ristimaki, A., Turpeenniemi-Hujanen, T. Association of cyclo-oxygenase-2 and matrix metaloproteinase -2 expression in human breast cancer. Breast cancer res treat 2005;89:215-220
25. Torng PL,Mao TL, Chan WY, Huang SC, Lin, CT. Prognostic significance of stromal metalloproteinase -2 in ovarian adenocarcinoma and its relation to carcinoma progression. Gynecol Oncol 2004;92:559-567
26. Vasala K, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer. Urology 2003;62:952-957
27. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455-465
28. Keleg S, Buchler P, Ludwig R, BuchlerMW,Friess H. Invasion and metastasis in pancreatic cancer. Mol Cancer 2003;2:14
29. Chauhan SS, Goldstein LJ, Gottesman MM. Expression of cathepsin L in human tumors. Cancer Res 1991;51:1478-1481
30. Mason RW, Johnson DA, Barrett AJ, Chapman HA. Elastinolytic activity of human cathepsin L. Biochem J 1986;233:925-927
31. Ohtani H. Stromal reaction in cancer tissue: Pathophysiologic significance of the expression of matrix-degrading enzymes in relation to matrix turnover and immune/inflammatory reactions. Pathol Int 1998;48:1-9
32. Werb Z. ECM and cell surface proteolysis: Regulating cellular ecology. Cell 1997;91:439-442
33. Liotta LA. Tumor invasion and metastases-role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res 1986;46:1-7
34. Bramhall SR, Neoptolemos JP, Stamp GW, Lemoine NR. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol 1997;182:347-355
35. Mohamed MM, Sloane BF. Cysteine cathepsins: Multifunctional enzymes in cancer. Nat Rev Cancer 2006;6:764-775
36. Hashimoto Y, Kondo C, Kojima T, Nagata H, Moriyama A, Hayakawa T, Katunuma N. Significance of 32-kDa cathepsin L secreted from cancer cells. Cancer Biother Radiopharm 2006;21:217-224
37. Rofstad EK, Mathiesen B, Kindem K, Galappathi K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res 2006;66: 6699-6707
38. Niedergethmann M, Hildenbrand R,Wolf G, Verbeke CS, Richter A, Post S. Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection. Int J Pancreatol 2000;28:31-39
39. Xu X, Yuan G, LiuW, Zhang Y, Chen W. Expression of cathepsin L in nasopharyngeal carcinoma and its clinical significance. Exp Oncol 2009;31:102-105
40. Foekens JA, Kos J, Peters HA, Krasovec M, Look MP, Cimerman N, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG. Prognostic significance of cathepsins B and L in primary human breast cancer. J Clin Oncol 1998;16:1013-1021
41. Juuti A, Lundin J, Nordling S, Louhimo J, Haglund C. Epithelial MMP-2 expression correlates with worse prognosis in pancreatic cancer. Oncology 2006;71:61-68
42. Yeghiazaryan M, Zybura-Broda K, Cabaj A, Wlodarczyk J, Slawinska U, Rylski M, Wilczynski GM. Fine-structural distribution of MMP-2 and MMP-9 activities in the rat skeletal muscle upon training: A study by high-resolution in situ zymography. Histochem Cell Biol 2012;138:75-87
43. Hill JW, Poddar R,Thompson JF, Rosenberg GA, Yang Y. Intranuclear matrix metalloproteinases promote DNA damage and apoptosis induced by oxygen-glucose deprivation in neurons. Neuroscience 2012;220:277-290
44. Kwan JA, Schulze CJ, Wang W, Leon H, Sariahmetoglu M, Sung M, Sawicka J, Sims DE, Sawicki G, Schulz R. Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB J 2004;18:690-692
45. Iki K, Tsutsumi M, Kido A, Sakitani H, Takahama M, Yoshimoto M, Motoyama M, Tatsumi K, Tsunoda T, Konishi Y. Expression of matrix metalloproteinase 2 (MMP-2), membrane-Type 1 MMP and tissue inhibitor of metalloproteinase 2 and activation of proMMP-2 in pancreatic duct adenocarcinomas in hamsters treated with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis 1999;20:1323-1329
46. Bloomston M, Zervos EE, Rosemurgy AS, 2nd. Matrix metalloproteinases and their role in pancreatic cancer: A reviewof preclinical studies and clinical trials. Ann Surg Oncol 2002;9:668-674
47. Koshiba T, Hosotani R, Wada M, Miyamoto Y, Fujimoto K, Lee JU, Doi R, Arii S, Imamura M. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer 1998;82:642-650
48. Kawamata H, Nakashiro K, Uchida D, Harada K, Yoshida H, Sato M. Possible contribution of active MMP2 to lymph-node metastasis and secreted cathepsin L to bone invasion of newly established human oral-squamous-cancer cell lines. Int J Cancer 1997;70:120-127
49. Gong YL, Xu GM, Huang WD, Chen LB. Expression of matrix metalloproteinases and the tissue inhibitors ofmetalloproteinases and their local invasiveness and metastasis inChinese human pancreatic cancer. J Surg Oncol 2000;73:95-99